Zabicipril
Code | Size | Price |
---|
TAR-T68171-1mg | 1mg | £295.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T68171-5mg | 5mg | £624.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T68171-10mg | 10mg | £860.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T68171-25mg | 25mg | £1,243.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T68171-50mg | 50mg | £1,653.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T68171-100mg | 100mg | £2,199.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
Zabicipril is a novel orally available angiotensin-converting enzyme inhibitor, a prodrug with antihypertensive activity following in vivo de-esterification.
CAS:
83059-56-7
Formula:
C23H32N2O5
Molecular Weight:
416.51
Pathway:
Endocrinology/Hormones
Purity:
0.9831
SMILES:
C([C@@H](N[C@H](C(OCC)=O)CCC1=CC=CC=C1)C)(=O)N2[C@H](C(O)=O)C3(CCC2(CC3)[H])[H]
Target:
RAAS
References
Naeije R, et al. Systemic and renal haemodynamic effects of angiotensin converting enzyme inhibition by zabicipril in young and in old normal men. Eur J Clin Pharmacol. 1993;44(1):35-9.